logo
Peach State Health Plan's $27.7M Investment Shows Strong Commitment to Member Wellness

Peach State Health Plan's $27.7M Investment Shows Strong Commitment to Member Wellness

ATLANTA, July 17, 2025 /PRNewswire/ — Peach State Health Plan (PSHP) has invested $27.7 million in additional Medicaid benefits from 2022 through 2024. Known as Value-Added Benefits (VABs), this includes services and activities designed to encourage healthy behaviors, strengthen care connections, and improve overall access to support. They are meaningful, real-life resources that help the health plan's most vulnerable members stay covered, well, and supported. Some restrictions and limitations may apply.
Over the past three years, 20% of PSHP's total VABs spending, or $5.4 million, was dedicated to vision care. Additional investments included $5.0 million for My Health Pays (Wellness Works), $4.3 million for Over-the-Counter (OTC) items, and $3.4 million for dental care.
'Our mission is rooted in supporting the communities we serve,' said Clyde White, President and CEO of Peach State Health Plan. 'This investment is another way we are delivering on that promise, providing our members with resources that go beyond basic healthcare, so they can live healthier lives.'
This year's VABs portfolio reflects on PSHP's commitment to supporting members' day-to-day needs and placing a stronger focus on removing barriers to care especially those tied to social drivers of health (SDOH). From job training and mental health tools to emergency childcare, every benefit is a touchpoint that shows members that they matter, and that Medicaid means more. Here is some of what's included in PSHP's 2025–2026 benefit cycle:
Up to six months of emergency childcare support provided through Quality Care for Children for eligible members facing urgent needs such as interviews, medical visits, or loss of care.
New 24/7 mental health support through Pyx Health gives members free, anytime access to emotional check-ins, encouragement, and real human connection.
Up to $240 each year to shop for everyday health essentials like cold medicine, toothpaste, and other care items at no cost through the Over-the-Counter (OTC) Benefit, making it easier to stay healthy while and stretch household budgets.
School-Break Grocery Allowance: Provides eligible Medicaid families with a prepaid card to help cover the cost of healthy groceries when school meals aren't available.
Free annual eye exam and $100 toward glasses, contacts or broken frames through our Vision Benefit.
Work-Ready Scholarships which equips eligible members with career-boosting job training and certifications through Goodwill Industries, helping them gain in-demand skills and enter the workforce with confidence.
'Peach State Health Plan is committed to going beyond traditional healthcare by addressing the everyday needs of our members,' said Tara Freeney, Senior Director of Commercial Operations. 'The investment in Value-Added Benefits reflects a dedication to improving quality of life across Georgia to meet members where they are and support healthier futures.'
PSHP's Value-Added Benefits are reviewed and updated every year for launch on July 1. To see a full list of available benefits, visit https://www.pshpgeorgia.com/value-added-services.html.
About Peach State Health Plan Peach State Health Plan is a care management organization that serves the needs of Georgians through a range of health insurance solutions. Peach State Health Plan serves the Medicaid and PeachCare for Kids® population in partnership with Georgia Families. The organization also focuses on under-insured and uninsured individuals through its federal insurance marketplace plan, Ambetter, and its Medicare Advantage Special Needs Plan. Peach State Health Plan is a Centene company, a leading healthcare enterprise committed to helping people live healthier lives. For more information visit www.pshpgeorgia.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Elixir MD Launches Australia & New Zealand Subsidiary in Exclusive Partnership with High Tech Medical Pty. Ltd.
Elixir MD Launches Australia & New Zealand Subsidiary in Exclusive Partnership with High Tech Medical Pty. Ltd.

Malaysian Reserve

time2 hours ago

  • Malaysian Reserve

Elixir MD Launches Australia & New Zealand Subsidiary in Exclusive Partnership with High Tech Medical Pty. Ltd.

IRVINE, Calif. and QUEENSLAND, Australia, Aug. 1, 2025 /PRNewswire/ — ELIXIR MD, Inc., a pioneer in advanced medical technology and proprietary treatment protocols for plastic surgery, today announced the formation of its wholly owned subsidiary in Australia and New Zealand, alongside an exclusive partnership with High Tech Medical Pty Ltd. to launch the ELIXIR MD™ device across the region. Ewan Mohammed, CEO of ELIXIR MD, Inc., stated:'We're proud to join forces with High Tech Medical—Australia and New Zealand's leading medical technology partner—to bring the ELIXIR MD™ device to facial surgery patients across one of the world's fastest-growing cosmetic markets. With more than 25 years of proven commitment to clinical excellence, High Tech Medical brings deep market insight and trusted relationships throughout the aesthetic medical community. Their long-standing success in introducing advanced technologies to Australians and New Zealanders makes them the ideal partner for ELIXIR MD, Inc.' Matt Moncrieff, Managing Director of High-Tech Medical Pty Ltd., added:'High Tech Medical is proud to work exclusively with ELIXIR MD, Inc., Ewan and the entire team have demonstrated a clear commitment to innovation and to reshaping the perioperative care model in plastic surgery. The ELIXIR MD™ device and its proprietary treatment protocols represent a new gold standard in post-surgical recovery by significantly reducing patient downtime and improving outcomes.' Australia and New Zealand: A Rising Market for Surgical Innovation Australian cosmetic surgery market reached approximately $1.8B in 2024, with expected growth to $3.9B by 2033, reflecting a CAGR of ~9.3% (IMARC Group, Rentech Digital). Facial cosmetic surgery—the category where ELIXIR MD™ is uniquely focused—is the fastest-growing segment of the cosmetic surgery market in Australia, with a projected CAGR of approximately 14.1% through 2030 (Grand View Research). Demand for face and eyelid surgeries (e.g. blepharoplasty, facelifts) is rising sharply in Australia and New Zealand, in key part driven by post-weight loss volume depletion and rejuvenation surgery (Daily Telegraph). About High Tech Medical Pty in 1999, High Tech Medical is one of the most respected providers of specialist aesthetic medical devices across Australia and New Zealand. With over two decades of leadership, the company has introduced breakthrough technologies that support minimally invasive treatments, reduce patient risk and downtime, and improve clinical outcomes. High Tech Medical is known for its consultative approach—helping practitioners select and integrate complex, high-performance systems into their practices with confidence. About ELIXIR MD, in Irvine, California, ELIXIR MD, Inc. is a medical technology company redefining recovery in plastic surgery through non-invasive, perioperative innovations. Now operating in 18 markets—including a wholly owned subsidiary in Australia and New Zealand—our FDA-cleared ELIXIR MD™ technology is built to support faster healing and better outcomes for surgeons and their patients worldwide.

National Report On Lived Experiences Of Women With Disabilities Will Be Out In August 2025
National Report On Lived Experiences Of Women With Disabilities Will Be Out In August 2025

Rakyat Post

time8 hours ago

  • Rakyat Post

National Report On Lived Experiences Of Women With Disabilities Will Be Out In August 2025

Subscribe to our FREE The potential for disability affects every individual; however, the existing infrastructure remains inadequate in effectively supporting those currently experiencing disability. This is one of the many findings reported in the new 'National Report on Monitoring the SDGs at 10 Years: Sexual and Reproductive Health and the Lived Experiences of Women and Individuals Assigned Female at Birth with Disabilities in Malaysia,' launched yesterday at Merdeka Space, Kuala Lumpur. According to The report consisted of stories by persons of disablilites who had spoken bravely of their experiences of medical neglect, institutional abandonment, and everyday resilience. It pointed out deep systemic gaps in services, access, and dignity for persons with disabilities, particularly women and assigned female at birth (AFAB) individuals. The irony is stark since Malaysia is positioning itself to become a high-income nation within the next couple of years but sidelined persons with disabilities in its national planning. While Malaysia promised to protect and promote equal rights by ratifying the United Nations Convention on the Rights of Persons with Disabilities (CRPD) in 2010, the reality on the ground paints a sobering picture. The full official report is set to be released to the public by the end of August 2025. For an idea of the challenges persons of disabilities go through, check out some of the stories below. READ MORE: READ MORE: READ MORE: READ MORE: READ MORE: Share your thoughts with us via TRP's . Get more stories like this to your inbox by signing up for our newsletter.

European drugmakers drop as Trump pushes for US price cuts
European drugmakers drop as Trump pushes for US price cuts

The Sun

time8 hours ago

  • The Sun

European drugmakers drop as Trump pushes for US price cuts

SINGAPORE: Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping executive order aimed at lowering prices. The letters were the latest setback for a sector still grappling with the prospect of tariffs outlined in the U.S.-EU trade deal that could cost the pharmaceutical industry between $13 billion and $19 billion. Trump called on 17 drugmakers to provide so-called most-favoured-nation prices to every patient enrolled in the government Medicaid health programme for low-income people, and to guarantee such pricing for new drugs. Shares of European drugmakers Sanofi, AstraZeneca , GSK, Merck KGaA and Novo Nordisk slipped between around 1% and 4% in early trading on Friday. Novo's 4% fall extends a selloff this week that started on Tuesday with a 28% plunge, wiping out $70 billion of its market value after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO. The companies were all sent letters by Trump, who gave them until September 29 to respond with binding commitments to those terms. U.S. drugmakers including Pfizer, Johnson & Johnson, Eli Lilly and Merck were also sent the letters. The European healthcare index was down 1.4% by 0731 GMT, its lowest since April. 'Trump's directive to the pharma companies will put them on the defensive and adds yet another layer of uncertainty for the sector which could also face import tariffs in time to come,' said Vasu Menon, managing director of investment strategy at OCBC. 'While Trump has set a deadline for these companies to comply, it remains to be seen if this is hard coded or if he will roll back some of his threats if these companies make an effort to engage him and soften his stance.' Analysts, lobbyists and drug pricing experts though said it seemed unlikely that the pharmaceutical companies would comply with Trump's demand to lower U.S. prices. The companies including Pfizer, AbbVie, and German Merck KGaA's U.S. division, EMD Serono, said they were open to working with the Trump administration. Trump's executive order in May directed drugmakers to lower medicine prices to align with what other countries pay, leading to some shift in how drugmakers look to sell their medicines. Swiss drugmaker Roche said last week it was considering selling its prescription medicines in the United States directly to consumers to lower costs for patients as part of talks with the U.S. government. - Reuters

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store